NCT05153915View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions

Liver TransplantationKidney Transplantation

Interventions

DRUG

Tacrolimus granules

Oral

DRUG

Tacrolimus granules

Oral

Trial Locations (7)

Unknown

Site CN86003, Beijing

Site CN86006, Changsha

Site CN86001, Guangzhou

Site CN86002, Shanghai

Site CN86007, Tianjin

Site CN86004, Wuhan

Site CN86005, Zhengzhou

All Listed Sponsors

lead

Astellas Pharma China, Inc.

INDUSTRY

NCT05153915 - A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients | Biotech Hunter | Biotech Hunter